United States-based GeneCentric Therapeutics has acquired Select ImmunoGenomics LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs, it was reported on Friday.

As a result of the transaction, it is claimed that the integrated company will have a comprehensive, integrated set of RNA-based solutions to improve drug development by identifying the right patients for oncology drugs, improving response rates and durability, and ultimately patient outcomes.

Financial terms of the deal were not revealed.